BrainStorm Cell Therapeutics Inc., a stem cell technology company that has its U.S. headquarters in Hackensack, has named a former Teva Pharmaceutical Industries Ltd. executive as its new chief financial officer, it announced Thursday.
The company, headquartered in Petach Tikvah, Israel, said Eyal Rubin will be responsible for all corporate finance and accounting activities. He had been vice president and head of corporate treasury for Teva since 2013, responsible for cash operations and management, as well as equity and debt capital market transactions.
“We are pleased to have Eyal join the BrainStorm team,” CEO and President Chaim Lebovits said in a prepared statement. “He is the third senior person to join our team in 2017, following the appointments of Dr. Ralph Kern as chief operating officer and chief medical officer, and Mary Kay Turner as vice president of patient advocacy and government affairs.
“We recently initiated a phase 3 clinical program investigating NurOwn in amyotrophic lateral sclerosis, and we currently anticipate top-line data in 2019. Eyal’s corporate finance experience with large commercial operations, including Teva Pharmaceuticals, will be invaluable for us.”
Rubin has served in executive roles for more than a dozen years, with companies including Cellcom Israel Ltd., IDT Carmel Inc., V-Secure Technologies and Sec2Wireless.
